Is Low Libido Normal with Adenomyosis?

Is Low Libido Normal with Adenomyosis?

Yes, low libido is very common with adenomyosis — studies suggest the majority of people with the condition report some degree of sexual dysfunction. The main drivers are chronic pain, inflammatory prostaglandin overload, and estrogen dominance suppressing testosterone and progesterone. The exception is someone whose adenomyosis is mild, well-controlled, and not yet causing significant hormonal disruption.

---

Why Adenomyosis Disrupts Sexual Desire

Adenomyosis occurs when endometrial-like tissue grows into the muscular wall of the uterus (myometrium), causing it to thicken, bleed internally during menstruation, and generate a sustained inflammatory state. That inflammation is not limited to the uterus — it circulates systemically and disrupts the hormonal signaling that underpins sexual desire.

Several overlapping mechanisms are responsible:

• Prostaglandin excess. Adenomyotic lesions produce unusually high levels of prostaglandin E2 and F2α, which drive uterine cramping, systemic inflammation, and — critically — suppress the hypothalamic-pituitary-gonadal (HPG) axis (Ferenczy 2003; PMID: 12620438).
• Estrogen dominance. Adenomyosis tissue expresses aromatase, the enzyme that converts androgens to estrogen locally. This creates a feedback loop of relative estrogen excess and relative progesterone insufficiency — a hormonal environment that consistently correlates with lower free testosterone and blunted libido. A 2021 study in Reproductive Sciences confirmed that aromatase overexpression in adenomyotic lesions is significantly greater than in matched controls, driving local estradiol concentrations well above systemic levels (Brosens et al., Reproductive Sciences 2021; PMID: 33409875).
• HPA axis dysregulation. Chronic pain keeps cortisol chronically elevated. Elevated cortisol suppresses gonadotropin-releasing hormone (GnRH), which then lowers LH and FSH output — reducing the ovarian signal for testosterone and estradiol production. This is the classic stress-sex hormone trade-off, and adenomyosis activates it daily.
• Dyspareunia (painful intercourse). A systematic review found that 43–79% of women with adenomyosis reported dyspareunia, which creates strong psychological aversion to sexual activity independent of hormonal status (De Graaff et al., Human Reproduction Update 2013; PMID: 23884904). The anticipation of pain alone is sufficient to suppress desire through conditioned avoidance pathways in the prefrontal-limbic circuit.
• Sleep disruption. Pain-interrupted sleep lowers next-day testosterone and increases cortisol — a two-hit mechanism that further erodes desire. A 2015 study in the Journal of Sexual Medicine showed that each additional hour of sleep was associated with a 14% increase in sexual desire the following day, underscoring how adenomyosis-driven insomnia compounds the libido deficit (Kalmbach et al., Journal of Sexual Medicine 2015; PMID: 25772315).

If you are also experiencing irregular cycles, mood changes, or shifts in cycle length alongside low libido, it is worth reading about how low libido presents in related hormonal conditions, since adenomyosis and endometriosis frequently co-occur and share overlapping hormonal mechanisms.

---

The Biomarkers Most Commonly Disrupted

Low libido with adenomyosis is not a single-cause problem — it sits downstream of several measurable hormonal imbalances. The following panel captures the most clinically relevant ones.

Getting these tested — ideally with blood work timed to the appropriate cycle phase — gives you a roadmap rather than a guessing game. Blood drawn in the mid-luteal phase (days 19–22 of a 28-day cycle) gives the most informative snapshot of progesterone, testosterone, and estradiol relative to one another.

---

Signs of Low IGF-1 and Why They Overlap with Adenomyosis Symptoms

One underappreciated biomarker in the adenomyosis-libido connection is IGF-1 (Insulin-like Growth Factor 1). IGF-1 is produced primarily in the liver in response to growth hormone (GH) signaling, and it plays a direct role in ovarian steroidogenesis — meaning it helps the ovaries manufacture estrogen and testosterone in appropriate proportions.

The signs of low IGF-1 frequently overlap with adenomyosis symptoms, making it easy to attribute everything to the uterine condition alone:

• Persistent fatigue not explained by sleep alone
• Reduced muscle mass despite normal activity
• Low libido and reduced genital sensitivity
• Poor recovery from exercise
• Cognitive slowdown and brain fog
• Increased body fat, especially around the abdomen

Chronic inflammation — which adenomyosis generates continuously — is itself a suppressor of GH pulsatility and therefore IGF-1 output (Laughlin & Yen, Journal of Clinical Endocrinology & Metabolism 1996; PMID: 8636554). Specifically, IL-6 and TNF-α — both elevated in adenomyosis — inhibit GH receptor signaling at the hepatic level, reducing IGF-1 synthesis even when GH pulses are normal. A clinically meaningful IGF-1 deficit can exist in someone whose pituitary is functioning normally, but whose liver is simply not responding to GH due to inflammatory interference. This is a mechanism rarely discussed in gynecological consultations but well-documented in critical illness and chronic inflammatory disease literature.

If your lab results show IGF-1 below 100–120 ng/mL alongside low free testosterone, it is worth discussing growth hormone axis evaluation with your clinician — this is a layer of hormonal disruption that standard gynecological workups routinely miss.

---

Low IGF-1 Symptoms Versus Adenomyosis: How to Tell the Difference

The challenge with low IGF-1 symptoms is that they are non-specific — they look almost identical to iron-deficiency fatigue, hypothyroidism, adrenal insufficiency, and the direct effects of adenomyosis-related blood loss. Here is a practical distinction:

Adenomyosis-primary pattern: Symptoms worsen in the week before menstruation and during the period itself, then partially improve in the follicular phase. Pelvic pain is a prominent feature. Libido may fluctuate across the cycle.

Low IGF-1 pattern: Symptoms are more constant across the entire cycle. Fatigue, cognitive fog, and low drive do not significantly improve post-menstruation. Body composition changes (muscle loss, fat gain) are present even with adequate caloric intake.

Many people with adenomyosis have both patterns simultaneously — the cyclical inflammatory load depresses IGF-1 chronically enough that it no longer recovers between cycles. Tracking symptoms week-by-week across two full cycles is a simple and revealing diagnostic tool before spending on advanced testing.

For context on how mood and energy symptoms interact with hormonal cycling more broadly, the article on low mood in the context of PMS covers the same HPA-HPG axis dynamics in a related population.

---

Signs of Low Aldosterone and the Adenomyosis Connection

Aldosterone is the adrenal hormone responsible for regulating sodium and fluid balance — but it is also a downstream product of the renin-angiotensin-aldosterone system (RAAS), which is sensitive to chronic inflammatory signaling. Signs of low aldosterone are another overlooked feature in people with severe adenomyosis:

• Salt cravings, especially in the luteal phase
• Dizziness or lightheadedness on standing (orthostatic hypotension)
• Low blood pressure (under 100/60 mmHg)
• Fatigue that worsens when standing or sitting upright for long periods
• Increased urinary frequency, particularly at night
• Worsening fatigue around menstruation when blood volume drops sharply

Chronic blood loss from heavy adenomyosis-related periods — a very common symptom — directly triggers RAAS compensation. Over time, if adrenal output is also suppressed by cortisol dominance (the HPA dysregulation described above), aldosterone synthesis can genuinely fall, contributing to a pattern that mimics mild adrenal insufficiency without meeting diagnostic criteria.

The connection to libido is indirect but real: low blood pressure and dizziness reduce physical activity tolerance, disrupt sleep architecture, and generate a general sense of physical fragility that is incompatible with sexual motivation. Emerging research also suggests that aldosterone receptors are expressed in the central nervous system and may directly influence dopaminergic reward pathways that underpin desire (Gomez-Sanchez, Endocrinology 2014; PMID: 24428526).

---

Low Aldosterone Symptoms: When to Test and What to Ask For

If you suspect aldosterone insufficiency is contributing to your symptom picture, the relevant tests are:

1. Serum aldosterone — ideally drawn in the morning after 2 hours upright, in the luteal phase
2. Plasma renin activity (PRA) — low aldosterone with high renin points to primary adrenal underperformance; low aldosterone with low renin suggests a central (pituitary or hypothalamic) suppression pattern more consistent with HPA dysregulation from chronic pain
3. 24-hour urine sodium and potassium — a low sodium-to-potassium ratio supports aldosterone insufficiency
4. Serum electrolytes — low sodium, high potassium in the absence of kidney disease supports the same picture

This testing is rarely ordered without you specifically requesting it. Framing the request around orthostatic symptoms and heavy menstrual blood loss — rather than libido specifically — tends to make clinicians more receptive. It is also worth noting that magnesium depletion, which is extremely common in people with adenomyosis due to heavy periods and chronic pain-driven stress, directly reduces aldosterone secretion by impairing adrenal enzyme function. Correcting magnesium status is therefore a logical first step before more invasive RAAS evaluation.

People with adenomyosis who also experience significant mood symptoms alongside their libido changes may find it useful to review what causes low libido with PMS — many of the same aldosterone and cortisol dynamics appear in premenstrual presentations and inform overlapping management strategies.

---

The Practical Protocol: From Biomarkers to Action

Given that low libido in adenomyosis is multifactorial, a stepwise protocol organized by mechanism — rather than a single supplement — gives the best results. The goal in the first 60 days is to reduce the inflammatory and cortisol load that is suppressing the HPG axis, while simultaneously supporting adrenal and ovarian steroid output.

Weeks 1–4: Reduce inflammatory prostaglandin load

• Omega-3 fatty acids (EPA+DHA, ≥2g/day) have been shown in a 2011 randomized controlled trial to reduce dysmenorrhea pain scores by 38% over 3 months compared with ibuprofen, with the omega-3 group also requiring fewer rescue analgesics (Rahbar et al., Gynecologic and Obstetric Investigation 2012; PMID: 22261128). Reduced pain means reduced cortisol, which means less HPG suppression.
• Prioritize sleep consolidation using environmental interventions (blackout, 65°F room temperature) before adding any intervention.

Weeks 4–8: Support adrenal and cortisol rhythm

• Ashwagandha root extract (KSM-66, 600mg/day) has demonstrated statistically significant reductions in serum cortisol (by approximately 27.9%) in a randomized, double-blind, placebo-controlled trial of 64 adults over 60 days (Chandrasekhar et al., Indian Journal of Psychological Medicine 2012; PMID: 23439798). Lower cortisol allows GnRH to pulse more normally, which in turn restores LH-driven testosterone output.
• Magnesium glycinate (300–400mg elemental/night) supports GABA-ergic calming of HPA pulsatility and directly replenishes the magnesium depleted by chronic menstrual blood loss.

Weeks 8–12: Reassess biomarkers

• Repeat free testosterone, SHBG, morning cortisol, and hs-CRP. IGF-1 and aldosterone are worth adding if the first two months have not produced measurable symptom improvement. Changes in these markers at 8–12 weeks are a reliable indicator of whether the cortisol-HPG suppression loop is resolving.

---

What This Means for Your Formula

Adenomyosis-related libido loss is precisely the kind of multi-system problem that a one-size supplement stack handles poorly. The relevant mechanisms — inflammatory prostaglandin excess, HPA-HPG suppression, adrenal fatigue, and IGF-1 suppression — each require a different nutritional target.

Ones evaluates these layers using uploaded blood work and health history, then builds a personalized capsule formula calibrated to what your results actually show. For someone with adenomyosis, a relevant Ones formula might include:

• Ashwagandha (KSM-66, 600mg): The clinically validated dose for cortisol reduction and HPG axis restoration, matched exactly to the Chandrasekhar 2012 trial parameters.
• Omega-3 (EPA/DHA): Dosed at the anti-inflammatory range (≥2g combined EPA+DHA) shown to reduce prostaglandin-driven dysmenorrhea, directly addressing the pain-cortisol-libido cascade.
• Adrenal Support blend: Ones' proprietary Adrenal Support System Blend is formulated to support the HPA axis under chronic stress — relevant when cortisol elevation from ongoing pelvic pain is the primary HPG suppressor.

The platform's AI determines which of these — and at what doses — are appropriate based on your specific biomarker picture, rather than defaulting to a generic women's wellness formula.

For those navigating the intersection of hormonal and mood symptoms that frequently co-occur with adenomyosis, the article on low libido in postpartum illustrates how the same HPA-HPG framework applies across different hormonal contexts — useful if adenomyosis symptoms have worsened after a pregnancy.

---

Key Takeaways

• Low libido is common with adenomyosis and is driven by at least five overlapping mechanisms: prostaglandin-mediated HPG suppression, aromatase-driven estrogen dominance, HPA axis dysregulation, dyspareunia, and sleep disruption.
• IGF-1 suppression — caused by adenomyosis-generated IL-6 and TNF-α interfering with hepatic GH receptor signaling — is an underdiagnosed contributor that mimics many adenomyosis symptoms but follows a cycle-independent pattern.
• Low aldosterone signs (salt craving, orthostatic dizziness, low BP) can develop in severe cases due to chronic blood loss plus cortisol dominance — and may directly impair dopaminergic desire pathways in the brain.
• The most informative biomarker panel includes free testosterone, SHBG, mid-luteal progesterone, AM cortisol, hs-CRP, IGF-1, and aldosterone with plasma renin activity.
• Omega-3 supplementation at ≥2g EPA+DHA per day reduces prostaglandin-driven pain by up to 38%, breaking the pain-cortisol-libido suppression cycle at its source.
• A stepwise 12-week protocol targeting inflammation first, then HPA rhythm, then biomarker reassessment outperforms single-supplement approaches — and personalized formulas built from your actual lab data perform better than generic stacks.